Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib

The standard of care for the first-line treatment of advanced gastrointestinal stromal tumor (GIST) is represented by imatinib, which is given daily at a standard dosage until tumor progression. Resistance to imatinib commonly occurs through the clonal selection of genetic mutations in the tumor DNA...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Front Pharmacol
المؤلفون الرئيسيون: Dalle Fratte, Chiara, Guardascione, Michela, De Mattia, Elena, Borsatti, Eugenio, Boschetto, Roberta, Farruggio, Angelo, Canzonieri, Vincenzo, Romanato, Loredana, Borsatti, Rachele, Gagno, Sara, Marangon, Elena, Polano, Maurizio, Buonadonna, Angela, Toffoli, Giuseppe, Cecchin, Erika
التنسيق: Artigo
اللغة:Inglês
منشور في: Frontiers Media S.A. 2020
الموضوعات:
Pharmacology
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7019050/
https://ncbi.nlm.nih.gov/pubmed/32116712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.00036
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة